Antibody Tools for Tumor Research: Glycosylation Modification & PSMA Targeting in Cancer Immune Evasion and Precision Therapy

Concept

Tumor development and progression are driven by two interconnected molecular hallmarks: aberrant post-translational modifications (PTMs) that enable cancer cell immune evasion and metabolic reprogramming, and tumor-specific antigen overexpression that defines precision oncology targets. Protein O-GlcNAcylation—a dynamic, reversible glycosylation PTM—regulates key tumor processes including immune evasion and aerobic glycolysis, with site-specific modification of proteins like ENO1 driving dual functional changes in tumor metabolism and PD-L1-mediated immune suppression. Prostate-Specific Membrane Antigen (PSMA)—a transmembrane glycoprotein overexpressed 100–1000-fold in prostate cancer—serves as an ideal precision target for prostate cancer diagnosis and targeted therapy, with its expression correlating directly with tumor malignancy. Unraveling these complex tumor mechanisms and advancing precision oncology demands highly specific, application-optimized antibodies: O-GlcNAcylation antibodies for dissecting glycosylation-mediated tumor immune evasion, and PSMA antibodies for prostate cancer diagnosis, prognosis and therapeutic development. As a global leader in life science reagents, ANT BIO PTE. LTD. delivers cutting-edge antibodies for both research areas via its Starter sub-brand (our flagship line for high-performance, rigorously validated antibodies): the O-Linked N-Acetylglucosamine Recombinant Rabbit mAb (S0B0373) for glycosylation modification research, and the PSMA Recombinant Rabbit Monoclonal Antibody (S0B2107) for prostate cancer precision oncology. Engineered on the proprietary S-RMab® recombinant rabbit monoclonal platform, these antibodies offer ultra-specificity, exceptional multi-platform performance and batch-to-batch consistency—serving as gold-standard tools for tumor biology research, cancer immune evasion mechanism dissection and prostate cancer precision diagnosis and therapy.

Research Frontiers

Glycosylation modification and PSMA targeting are at the forefront of modern tumor research, spanning cancer immunology, metabolic reprogramming and precision oncology. ANT BIO PTE. LTD.’s specialized O-GlcNAc and PSMA antibodies enable transformative discoveries in key high-impact research frontiers that are redefining our understanding of tumor biology and cancer treatment:

O-GlcNAcylation in Tumor Immune Evasion & Metabolic Reprogramming

1. Site-specific glycosylation function dissection: Uncovering how distinct O-GlcNAcylation sites on a single protein (e.g., ENO1 Thr19 vs. Ser249) drive divergent tumor functions—metabolic reprogramming vs. immune evasion—and identifying novel site-specific modification targets for cancer therapy.
2. Glycosylation-immune checkpoint crosstalk: Elucidating the molecular mechanisms by which O-GlcNAcylation regulates immune checkpoint protein (e.g., PD-L1) stability and expression, and exploring how glycosylation targeting can reverse immune suppression in the tumor microenvironment (TME).
3. Metabolic-immune synergy in the TME: Studying how glycosylation-mediated aerobic glycolysis (Warburg effect) alters the TME (e.g., lactate accumulation) to inhibit anti-tumor immune cell function, and developing combination strategies to target both metabolic and immune pathways.
4. Glycosylation as a predictive biomarker: Validating O-GlcNAc modification levels of key proteins as predictive biomarkers for immune checkpoint inhibitor (ICI) response and resistance, enabling personalized immunotherapy selection.
5. Glycosyltransferase/glycosidase targeted therapy: Developing small-molecule inhibitors of O-GlcNAc transferase (OGT) or O-GlcNAcase (OGA) that selectively block oncogenic glycosylation sites, and using O-GlcNAc antibodies to evaluate their efficacy and mechanism of action.

PSMA Targeting in Prostate Cancer Precision Oncology

1. Next-generation molecular imaging: Engineering radionuclide-labeled PSMA antibodies for high-sensitivity PET imaging of minimal residual disease and biochemically recurrent prostate cancer, enabling earlier intervention and treatment monitoring.
2. Novel PSMA-targeted therapeutics: Developing PSMA antibody-drug conjugates (ADCs), bispecific antibodies and CAR-T cell therapies for castration-resistant prostate cancer (CRPC), the most aggressive and treatment-refractory form of the disease.
3. PSMA-based liquid biopsy: Creating antibody-driven platforms for capturing PSMA-expressing circulating tumor cells (CTCs) and extracellular vesicles (EVs) in peripheral blood, providing non-invasive disease monitoring and treatment response assessment.
4. PSMA as a pan-tumor vascular target: Exploring PSMA expression in the neovascular endothelial cells of other solid tumors, and developing PSMA-targeted anti-angiogenic therapies for a broad range of cancers.
5. PSMA companion diagnostics: Validating PSMA expression levels as a companion diagnostic biomarker to identify prostate cancer patients most likely to benefit from PSMA-targeted therapies and ICIs.

Research Significance

Aberrant O-GlcNAc glycosylation and PSMA overexpression are defining molecular features of cancer, with research into these targets driving a paradigm shift in our understanding of tumor biology and the development of next-generation cancer therapies. ANT BIO PTE. LTD.’s O-GlcNAc and PSMA antibodies amplify the scientific and translational significance of this research, with far-reaching implications for cancer diagnosis, therapy and precision medicine:

O-GlcNAc Glycosylation: Unlocking the Mechanisms of Tumor Immune Evasion

1. A unifying mechanism for metabolic and immune dysregulation: O-GlcNAcylation is the first identified PTM that drives both tumor metabolic reprogramming (Warburg effect) and immune evasion (PD-L1 stabilization) via site-specific modification of a single protein (ENO1), providing a unifying target for combination therapy.
2. Reversing immune checkpoint inhibitor resistance: Glycosylation-mediated PD-L1 stabilization is a novel mechanism of ICI resistance; targeting O-GlcNAcylation offers a new strategy to restore anti-tumor immunity in resistant tumors.
3. Tumor-specific therapeutic targeting: O-GlcNAcylation is aberrantly upregulated in most cancers but tightly regulated in normal cells, making it a tumor-specific target with minimal off-target effects.
4. Expanding the repertoire of immunotherapy combinations: Glycosylation-targeted therapies can be combined with ICIs, chemotherapy and targeted therapy to create synergistic anti-tumor effects, addressing the unmet clinical need for effective combination strategies in advanced cancer.

PSMA: Transforming Prostate Cancer Precision Diagnosis and Therapy

1. The gold-standard precision oncology target for prostate cancer: PSMA is overexpressed in nearly all prostate cancers, with expression levels correlating with malignancy—making it a highly specific and sensitive target for diagnosis and therapy with minimal normal tissue expression.
2. Revolutionizing prostate cancer detection: PSMA-based molecular imaging has significantly improved the detection of metastatic and recurrent prostate cancer, outperforming conventional imaging modalities and enabling personalized treatment planning.
3. New hope for CRPC patients: PSMA-targeted therapies (e.g., radioligand therapy, ADCs) have shown remarkable efficacy in CRPC patients who have failed multiple lines of treatment, providing a life-extending treatment option for this lethal disease.
4. A blueprint for solid tumor targeted therapy: The success of PSMA-targeted antibody technology serves as a model for developing antibody-based diagnostics and therapeutics for other solid tumors with tumor-specific antigen overexpression, advancing the field of precision oncology.

Together, these antibody tools are enabling researchers to dissect the most complex molecular mechanisms of cancer and develop the next generation of precision diagnostics and therapeutics that will transform cancer patient care.

Related Mechanisms, Research Methods & Product Applications

1. O-GlcNAc Glycosylation: A Dynamic PTM Regulating Tumor Immune Evasion and Metabolic Reprogramming

O-GlcNAcylation is a reversible, nutrient-sensing glycosylation PTM that involves the covalent attachment of an N-acetylglucosamine (GlcNAc) moiety to serine/threonine residues of intracellular proteins, catalyzed by O-GlcNAc transferase (OGT) and reversed by O-GlcNAcase (OGA). Unlike other glycosylation modifications, O-GlcNAcylation is not restricted to the cell surface or secretory pathway—it occurs in the nucleus and cytoplasm of all eukaryotic cells, and its levels are directly regulated by intracellular UDP-GlcNAc concentrations (a product of glucose and glutamine metabolism), making it a cellular nutrient sensor.

In cancer cells, aberrant O-GlcNAcylation drives tumor development and progression by regulating key biological processes, with the most well-characterized example being the site-specific modification of enolase 1 (ENO1):

• ENO1 Thr19 O-GlcNAcylation: Promotes ENO1 dimer formation and enhances its glycolytic enzyme activity, driving the Warburg effect (aerobic glycolysis) in tumor cells. This metabolic reprogramming produces large amounts of lactate, which accumulates in the TME and directly inhibits the cytotoxic function of T cells and natural killer (NK) cells.
• ENO1 Ser249 O-GlcNAcylation: Blocks the interaction between ENO1 and PD-L1, inhibiting the E3 ubiquitin ligase STUB1-mediated ubiquitination and degradation of PD-L1. This leads to abnormal PD-L1 accumulation on the tumor cell surface, which binds to PD-1 on T cells and suppresses T cell activation and proliferation—inducing T cell tolerance and immune evasion.

This site-specific dual regulation creates a synergistic effect in the TME: metabolic reprogramming and immune suppression work together to create a tumor-permissive environment that enables cancer cell proliferation, survival and metastasis.

2. O-GlcNAc-Specific Antibodies: Indispensable Tools for Tumor Immunology and Glycosylation Research

O-GlcNAc-specific antibodies are the cornerstone of glycosylation research, enabling the detection, quantification and functional characterization of this dynamic PTM in tumor cells and the TME. Their core applications span basic tumor biology research, mechanism dissection and translational oncology:

1. Modification site identification: Immunoprecipitation (IP) combined with mass spectrometry (MS) to systematically identify O-GlcNAcylation sites on key oncoproteins (e.g., ENO1, PD-L1, c-Myc) in cancer cells.
2. Dynamic modification detection: Western blot (WB) and immunofluorescence (IF) to quantify O-GlcNAc modification levels in tumor cells and tissues under different physiological and pathological conditions (e.g., nutrient deprivation, immune stimulation).
3. Subcellular localization analysis: Immunohistochemistry (IHC) and IF to map the subcellular distribution of O-GlcNAc-modified proteins in the nucleus and cytoplasm of tumor cells, and to study their localization changes in the TME.
4. Protein interaction studies: Co-IP to identify the interaction networks between O-GlcNAc-modified proteins and other molecules (e.g., ENO1-PD-L1, OGT-transcription factors), elucidating the molecular mechanisms of glycosylation-mediated tumor function.
5. Clinical sample analysis: IHC and WB to detect O-GlcNAc modification levels in human tumor tissue samples, exploring their potential as diagnostic, prognostic and predictive biomarkers for cancer.
6. Drug development and evaluation: High-throughput screening of OGT/OGA inhibitors using O-GlcNAc antibodies, and evaluating the effects of these inhibitors on glycosylation levels, tumor metabolism and immune evasion in preclinical models.

3. PSMA: Structural, Functional and Expression Characteristics in Prostate Cancer

Prostate-Specific Membrane Antigen (PSMA, also known as glutamate carboxypeptidase II/FOLH1) is a 750-amino acid type II transmembrane glycoprotein with a unique three-domain structure:

• A short 19-amino acid intracellular domain
• A 24-amino acid transmembrane domain
• A large 707-amino acid extracellular domain (divided into protease, apical and dimerization domains), which contains the zinc-dependent metalloprotease active site and substrate-binding region.

Under physiological conditions, PSMA catalyzes the hydrolysis of the brain peptide N-acetyl-aspartyl-glutamate (NAAG) and the cleavage of glutamate residues from polyglutamate folate in the small intestine. Its expression pattern is the key to its utility as a prostate cancer target:

• Physiological expression: Restricted to normal prostate epithelial cells, renal proximal tubules, small intestinal brush border membranes and a subset of neural cells (astrocytes, Schwann cells).
• Cancer-specific overexpression: Upregulated 100–1000-fold in prostate cancer cells compared to normal prostate tissue, with expression levels positively correlated with tumor malignancy (highest in poorly differentiated, metastatic and castration-resistant prostate cancer).
• Tumor vascular expression: Expressed in the neovascular endothelial cells of prostate cancer and other solid tumors, expanding its potential as a pan-tumor anti-angiogenic target.

4. PSMA Antibodies: Diagnostic and Therapeutic Mechanisms in Prostate Cancer

PSMA-specific antibodies are the gold-standard tools for prostate cancer precision diagnosis and targeted therapy, with distinct mechanisms of action that address unmet clinical needs in prostate cancer patient care:

Diagnostic Mechanisms

1. Histopathological detection: IHC staining for PSMA expression in prostate needle biopsies and radical prostatectomy specimens to assist in tumor grading, staging, Gleason scoring and differential diagnosis of poorly differentiated prostate cancer.
2. Molecular imaging: Radionuclide-labeled PSMA antibodies for PET imaging, enabling high-sensitivity and high-specificity localization of primary and metastatic prostate cancer lesions—including small bone and lymph node metastases undetectable by conventional imaging.
3. Liquid biopsy: PSMA antibody-based capture systems to isolate PSMA-expressing CTCs and EVs from peripheral blood, providing a non-invasive method for monitoring disease progression and treatment response.
4. Therapy stratification: Quantitative detection of PSMA expression levels in tumor tissue to identify patients who will benefit from PSMA-targeted therapies (e.g., radioligand therapy, ADCs), enabling personalized treatment decision-making.

Therapeutic Mechanisms

1. Antibody-Dependent Cellular Cytotoxicity (ADCC): The Fc region of PSMA antibodies binds to Fc receptors on immune effector cells (NK cells, macrophages), triggering the direct lysis of PSMA-expressing tumor cells.
2. Complement-Dependent Cytotoxicity (CDC): PSMA antibody binding to tumor cell surface PSMA activates the complement cascade, forming membrane attack complexes (MACs) that induce tumor cell death.
3. Signal pathway interference: Blocking PSMA’s enzymatic activity or downstream signaling pathways (PI3K/Akt/MAPK) to disrupt prostate cancer cell metabolism, proliferation and survival.
4. Targeted drug delivery: Conjugation of PSMA antibodies with cytotoxic drugs, radionuclides or immunomodulatory molecules to create ADCs and radioligand therapies that deliver therapeutics directly to tumor cells—maximizing anti-tumor efficacy and minimizing systemic toxicity.
5. Bispecific antibody/CAR-T therapy: Engineering bispecific antibodies that target both PSMA and T cell surface receptors (e.g., CD3), or PSMA-directed CAR-T cells, to redirect the immune system to specifically recognize and kill PSMA-positive prostate cancer cells.

ANT BIO PTE. LTD.’s Starter Antibodies: Core Products for Tumor Research

ANT BIO PTE. LTD.’s Starter sub-brand delivers two industry-leading antibodies for O-GlcNAc glycosylation and PSMA prostate cancer research—both engineered on the proprietary S-RMab® recombinant rabbit monoclonal platform and rigorously validated for ultra-specificity, exceptional multi-platform performance and batch-to-batch consistency. These antibodies are optimized for the unique experimental and clinical needs of tumor biology research, cancer immunology and prostate cancer precision oncology, and serve as gold-standard tools for basic and translational cancer research.

1. O-Linked N-Acetylglucosamine Recombinant Rabbit mAb (S0B0373)

This high-performance antibody is specifically designed for O-GlcNAc glycosylation modification research, with exceptional specificity for O-GlcNAc modifications on serine/threonine residues and broad target coverage across all O-GlcNAc-modified proteins.

Core Product Advantages

Key Research Applications

• O-GlcNAc modification omics: IP-MS to systematically identify and validate O-GlcNAc-modified protein profiles in cancer cells/tissues under specific physiological/pathological conditions.
• Tumor signaling pathway dissection: Studying how O-GlcNAcylation cross-regulates phosphorylation to modulate oncogenic signaling pathways (e.g., PI3K/Akt, MAPK, Wnt/β-catenin) in cancer cells.
• Metabolism-immune crosstalk research: Exploring how nutrient sensing via O-GlcNAcylation regulates tumor metabolism and immune evasion in the TME.
• Cancer biomarker discovery: Detecting O-GlcNAc modification levels in human tumor samples to identify novel diagnostic, prognostic and predictive biomarkers for cancer.
• Drug development: Screening and evaluating OGT/OGA inhibitors, and assessing their effects on O-GlcNAcylation levels, tumor growth and immune evasion in preclinical cancer models.
• Disease mechanism research: Studying aberrant O-GlcNAcylation in other diseases (Alzheimer’s, diabetes, cardiovascular disease) beyond cancer.

2. PSMA Recombinant Rabbit Monoclonal Antibody (S0B2107)

This ultra-specific antibody is the gold-standard tool for prostate cancer precision oncology research and clinical pathology, with exceptional specificity for the PSMA extracellular domain and clear membrane staining in formalin-fixed, paraffin-embedded (FFPE) prostate tissue sections.

Core Product Advantages

Key Research & Clinical Applications

• Prostate cancer pathological diagnosis: IHC detection in needle biopsies and radical specimens for Gleason scoring, tumor staging and prognosis assessment.
• Metastatic prostate cancer detection: Identifying prostate cancer origins in lymph node, bone and other metastatic sites—critical for differential diagnosis when PSA and other indicators are atypical.
• PSMA-targeted therapy development: Preclinical research to validate target expression, screen patients and explore efficacy-related biomarkers for PSMA ADCs, CAR-T cell therapy and radioligand therapy.
• Molecular imaging probe development: Validating target binding specificity for the development and evaluation of PSMA-based PET imaging agents and other molecular imaging probes.
• Tumor biology research: Studying PSMA’s role in prostate cancer initiation, progression, metastasis and TME regulation, and its expression in the neovasculature of other solid tumors.

Brand Mission of ANT BIO PTE. LTD.

At ANT BIO PTE. LTD., our core mission is to empower breakthroughs in tumor biology research, cancer immunology and precision oncology by delivering high-quality, highly specific and rigorously validated life science reagents and comprehensive solutions. As a leading global provider of research tools, we have built three specialized, complementary sub-brands that cover the full spectrum of life science research needs, creating a seamless one-stop procurement experience for academic researchers, pathologists, biotech companies, pharmaceutical institutions and translational research labs worldwide:

• Starter: Our flagship sub-brand for high-performance antibodies and affinity tools, offering tumor research antibodies (O-GlcNAc S0B0373, PSMA S0B2107), neurodegenerative disease antibodies, epigenetic modification antibodies and isoform-specific recombinant rabbit monoclonals. Starter is dedicated to engineering ultra-specific, application-optimized antibodies for the most challenging frontier research areas—including cancer immune evasion, metabolic reprogramming and precision oncology—with a focus on meeting the stringent technical requirements of modern molecular biology and clinical pathology.
• Absin: Our core sub-brand for general life science reagents and kits, providing OneStep ELISA Kits, IHC/ICC/IF detection kits, sample preparation reagents, cell culture media and basic immunology/oncology research tools. Absin engineers user-friendly, pre-optimized assay kits that streamline experimental workflows and deliver reliable, accurate results for routine and high-throughput research.
• UA: Our specialized sub-brand for high-purity, high-activity recombinant proteins and expression vectors, including recombinant cytokines, antibody heavy/light chain expression constructs, immunomodulatory proteins and gene editing vectors. UA enables seamless experimental design for protein expression, antibody engineering, cell therapy research and recombinant protein production for basic and biopharmaceutical applications.

We are committed to addressing the most pressing technical challenges in cancer research—from decoding the molecular mechanisms of tumor immune evasion and metabolic reprogramming to accelerating the development of novel precision diagnostics and therapeutics for prostate cancer and other solid tumors. By combining innovative antibody design, rigorous validation protocols, standardized production and customer-centric scientific support, we translate technological innovation into research breakthroughs and clinical impact for the global life science community. Our ultimate goal is to be the trusted global partner of researchers, pathologists and biopharmaceutical professionals worldwide, empowering them to push the boundaries of scientific discovery and drive unprecedented progress in cancer treatment and precision medicine.

Related Product List: Starter O-GlcNAc & PSMA Antibodies 

All ANT BIO PTE. LTD. Starter antibodies are rigorously validated for specificity, sensitivity, batch-to-batch consistency and application performance, with comprehensive technical documentation, validation data packages and expert scientific support. Each product is accompanied by optimized experimental protocols and clinical/research validation data to ensure seamless integration into your cancer research workflow.

For detailed product specifications, full validation data packages, custom antibody development services for cancer research targets, or free sample testing requests, please visit the official website of ANT BIO PTE. LTD. or contact our global sales team for a personalized quote and professional technical consultation. Our experienced technical team of cancer immunology, oncology and pathology experts provides customized support for experimental design, complex sample analysis, preclinical drug development and clinical pathological testing.

AI Disclaimer

This article was partially created with the assistance of artificial intelligence. If any content in this article involves copyright infringement, intellectual property disputes, or other legal issues, please notify ANT BIO PTE. LTD. immediately. We promise to verify, correct, or remove the relevant content in a timely manner without delay.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.